Financial writers often lament that shareholders are too passive with respect to exercising their rights to oppose management decisions tha...

Financial writers often lament that shareholders are too passive with respect to exercising their rights to oppose management decisions tha...
When Elan (NYSE: ELN ) announced back in February that it was selling its interests in Tysabri to Biogen Idec (Nasdaq: BIIB ) my biggest ...